Federal health regulators say the toxic side effects of an experimental cancer drug from Onyx Pharmaceuticals may outweigh the drug’s benefits for patients with a type of blood cancer. The Food and Drug Administration warned that patients taking the drug carfilzomib in company studies had a high rate of heart and lung side effects, some which were fatal. The FDA posted its review of the drug ahead of a Wednesday meeting of its cancer drugs panel.
